BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/24/2022 10:56:44 AM | Browse: 350 | Download: 683
 |
Received |
|
2022-03-18 14:14 |
 |
Peer-Review Started |
|
2022-03-18 14:16 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2022-05-12 08:14 |
 |
Revised |
|
2022-05-20 14:18 |
 |
Second Decision |
|
2022-07-21 03:06 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2022-07-26 22:44 |
 |
Articles in Press |
|
2022-07-26 22:44 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2022-09-16 05:50 |
 |
Publish the Manuscript Online |
|
2022-09-24 10:56 |
ISSN |
2220-3249 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Infectious Diseases |
Manuscript Type |
Minireviews |
Article Title |
Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment
|
Manuscript Source |
Invited Manuscript |
All Author List |
Anna Maria Spera |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Anna Maria Spera, Doctor, PhD, Doctor, Doctor, Postdoctoral Fellow, Infectious Disease Unit, Universitary Hospital OORR San Giovanni di Dio e Ruggi d'Aragona, Largo Ippocrate, Salerno 84131, Italy. annamariaspera@hotmail.it |
Key Words |
Hepatitis B Virus infection; Reactivation; Occult B infection; Chronic B infection; Immunosuppression; Disease-modifying antirheumatic drugs |
Core Tip |
Hepatitis B Virus (HBV) is a major public health challenge requiring an urgent response. Patients with overt or occult HBV infection can undergo HBV reactivation (HBVr) in course of immunosuppressive treatments, also used in rheumatologic, gastrointestinal, neurological and dermatological settings and to treat Sars severe acute respiratory syndrome coronavirus 2 infection. The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence. The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status. |
Publish Date |
2022-09-24 10:56 |
Citation |
Spera AM. Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment. World J Virol 2022; 11(5): 275-282 |
URL |
https://www.wjgnet.com/2220-3249/full/v11/i5/275.htm |
DOI |
https://dx.doi.org/10.5501/wjv.v11.i5.275 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345